<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9787">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01735305</url>
  </required_header>
  <id_info>
    <org_study_id>SYNH-20121113</org_study_id>
    <nct_id>NCT01735305</nct_id>
  </id_info>
  <brief_title>Optimized Scheme About Antiplatelet Therapy in Patients With Coronary Heart Disease</brief_title>
  <acronym>Sacred</acronym>
  <official_title>Study of Optimized Scheme About Antiplatelet Therapy in Patients With Coronary Heart Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shenyang Northern Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Guangdong General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shenyang Northern Hospital</source>
  <oversight_info>
    <authority>China: Ministry of Health</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators designed a clinical randomized trials,which established a registration
      platform of antiplatelet therapy in patients with coronary heart disease,in order to
      understand current situation of antithrombotic treatment in our country at present stage,and
      to evaluate the popularity rate of antiplatelet therapy which is followed domestic and
      international relevant guidelines in our country,finally analyse events risk factors of
      blood clot and bleeding after antiplatelet therapy in patients with coronary heart disease.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Anticipated">July 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>death</measure>
    <time_frame>12month</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Cardiovascular death  Non cardiovascular death  Unexplained death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular events</measure>
    <time_frame>12month</time_frame>
    <safety_issue>No</safety_issue>
    <description>Lethal myocardial infarction PTCA or CABG hemorrhage Deadly stroke</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">8000</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Positive group</arm_group_label>
    <description>The groups who Clinical events happened</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Negative Group</arm_group_label>
    <description>The groups who Clinical events have not happened</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patient of coronary heart disease
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Clinical diagnosis of coronary heart disease

          2. Age should be full of 18 years old

          3. Have been taking  anti-platelet  drugs

          4. Informed consent signed

        Exclusion Criteria:

          1. With severe disease and life expectancy 6 months or less

          2. The researchers think follow-up more difficult situation (travel, speech or mental
             disorder, etc.)

          3. Taking part in an intervening clinical research
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yaling Han, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shenyang Northern Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yaling Han, MD</last_name>
    <phone>+86-24-23922184</phone>
    <email>13998847715@qq.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Guangdong General Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jiyan Chen, MD</last_name>
      <phone>15920520902</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northern Hospital</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yaling Han, Dr</last_name>
      <phone>+86-24-23922184</phone>
      <email>hanyal@263.net</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <lastchanged_date>November 27, 2012</lastchanged_date>
  <firstreceived_date>November 12, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shenyang Northern Hospital</investigator_affiliation>
    <investigator_full_name>Yaling Han</investigator_full_name>
    <investigator_title>Head of Cardiology</investigator_title>
  </responsible_party>
  <keyword>Coronary Artery Disease</keyword>
  <keyword>antiplatelet therapy</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
